Chiasma Inc (CHMA) Gross Profit Margin starting from the first quarter 2021 to first quarter 2020, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Chiasma Inc   (NASDAQ: CHMA)


Chiasma Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CHMA Gross Profit Margin (Mar 31 2021)
Q1 		(Dec 31 2020)
Q4 		(Sep 30 2020)
Q3 		(Jun 30 2020)
Q2 		(Mar 31 2020)
Q1
Y / Y Revenue Change -
Seq. Revenue Change 99.59 %
Revenue In Millions $1.92
Gross Profit Margin 96.52 %
Gross Profit Margin Total Ranking # 125
Gross Profit In Millions $1.86
Y / Y Gross Profit Change -
Seq. Gross Profit Change 104.97 %


Commenting First Quarter 2021 Gross Profit Margin
Chiasma Inc Gross Profit grew by 104.97 % in Q1 sequentially to 2 millions, while Revenue increased by 99.59 %, this led to improvement in the company's Gross Profit Margin to 96.52 %, above the Chiasma Inc average Gross Profit Margin.


Observing first quarter 2021 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 125, from total ranking in the previous quarter at 169.
Learn about Gross Margin
CHMA's Gross Profit Margin first quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 23
Overall # 119

Gross Profit Margin Statistics
High Average Low
97.89 % 96.13 % 93.98 %
(Sep 30 2020)   (Dec 31 2020)


CHMA Gross Income Trends • More of CHMA's Profitabilty Ratios • CHMA Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
CHMA's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
CHMA's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for CHMA's Competitors
Gross Profit Margin Profit Margin for Chiasma Inc 's Suppliers
Gross Profit Margin Profit Margin for CHMA's Customers

You may also want to know
CHMA's Annual Growth Rates CHMA's Profitability Ratios CHMA's Asset Turnover Ratio CHMA's Dividend Growth
CHMA's Roe CHMA's Valuation Ratios CHMA's Financial Strength Ratios CHMA's Gross Profit Growth
CHMA's Roa CHMA's Inventory Turnover Ratio CHMA's Growth Rates CHMA's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2021, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2021 MRQ Gross ProfitMar 31 2021 MRQ Revenue
Vistagen Therapeutics Inc   99.98 %$ 0.442  Millions$ 0.442  Millions
Macrogenics Inc   99.90 %$ 16.864  Millions$ 16.881  Millions
Karyopharm Therapeutics Inc   99.65 %$ 23.178  Millions$ 23.260  Millions
Rigel Pharmaceuticals Inc  99.61 %$ 80.702  Millions$ 81.018  Millions
Deciphera Pharmaceuticals Inc   99.12 %$ 24.934  Millions$ 25.156  Millions
Intercept Pharmaceuticals inc   99.01 %$ 80.851  Millions$ 81.661  Millions
Ptc Therapeutics inc   98.81 %$ 116.542  Millions$ 117.942  Millions
Myovant Sciences Ltd   98.78 %$ 24.304  Millions$ 24.605  Millions
Omeros Corporation  98.75 %$ 20.798  Millions$ 21.061  Millions
Global Blood Therapeutics Inc.  98.50 %$ 38.459  Millions$ 39.043  Millions
Corcept Therapeutics Inc  98.40 %$ 78.169  Millions$ 79.437  Millions
Y mabs Therapeutics inc   98.27 %$ 5.290  Millions$ 5.383  Millions
Sellas Life Sciences Group Inc   98.19 %$ 5.440  Millions$ 5.540  Millions
Adamas Pharmaceuticals Inc  98.01 %$ 18.926  Millions$ 19.311  Millions
Acadia Pharmaceuticals Inc   97.95 %$ 104.369  Millions$ 106.554  Millions
Ionis Pharmaceuticals Inc   97.69 %$ 109.029  Millions$ 111.607  Millions
Nabriva Therapeutics Plc  97.55 %$ 2.467  Millions$ 2.529  Millions
Travere Therapeutics Inc   96.53 %$ 45.762  Millions$ 47.407  Millions
Chiasma Inc   96.52 %$ 1.857  Millions$ 1.924  Millions
Strongbridge Biopharma plc  95.10 %$ 7.971  Millions$ 8.382  Millions
Zogenix Inc   95.06 %$ 13.008  Millions$ 13.684  Millions
Siga Technologies Inc  94.79 %$ 4.563  Millions$ 4.814  Millions
Ultragenyx Pharmaceutical Inc   94.78 %$ 94.207  Millions$ 99.395  Millions
Aurinia Pharmaceuticals Inc   94.75 %$ 0.866  Millions$ 0.914  Millions
Serina Therapeutics Inc   94.64 %$ 0.053  Millions$ 0.056  Millions
Beone Medicines Ltd   94.61 %$ 573.187  Millions$ 605.872  Millions
Vaxxinity Inc   94.12 %$ 0.016  Millions$ 0.017  Millions
United Therapeutics Corporation  93.93 %$ 356.100  Millions$ 379.100  Millions
Aveo Pharmaceuticals Inc   92.81 %$ 1.782  Millions$ 1.920  Millions
Neximmune Inc   92.81 %$ 2.251  Millions$ 2.425  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.